Nav: Home

The first AI system for human embryonic state analysis is available for testing

July 05, 2016

Tuesday, July 5, 2016, Baltimore, MD - At Mensa Annual Gathering 2016, the annual event of the largest and oldest high IQ society transpiring in San Diego from June 29th to July 3rd, Dr. Michael West, CEO of BioTime, Inc announced the launch of a beta version of Embryonic.AI, an artificially intelligent system for analyzing the embryonic state of human cell samples using gene expression data. The first implementation of Embryonic.AI was launched by LifeMap Discovery, Inc, a subsidiary of BioTime, Inc and is freely available for beta testing. Scientists and companies from all over the world are welcome to test their stem cell and adult cell samples using Embryonic.AI and discuss collaboration alternatives. A brief video provides a general introduction to the Embryonic.AI system is available at https://www.youtube.com/watch?v=MbgZSDqPe78 and BioTime's press release is available at http://finance.yahoo.com/news/BioTime-presents-online-applying-artificial-120000254.html

"BioTime harnesses the largest collection of highest-quality gene expression data coming from scrupulously designed and controlled cell differentiation experiments we have seen to date. It was large enough to train a complex architecture of deep neural networks to work as a classifier and a predictor of the embryonic state. We recently tested Embryonic.AI using mouse data and noticed surprising results showing the capabilities of this system in cross-species analysis. Research projects using Embryonic.AI may transform our understanding of cancer and other diseases and possible developments in reinforcement learning may help navigate and control cellular differentiation states", said Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine, Inc.

The system utilizes a sophisticated architecture of multi-class deep neural networks (DNNs) and DNN ensembles trained on thousands of samples of carefully selected cells of multiple classes: embryonic stem cells, induced pluripotent stem cells, progenitor stem cells, adult stem cells and adult cells to recognize the class and embryonic state of the sample, achieving high accuracy in simulations. The unique samples were generated using standardized protocols by BioTime, Inc. and profiled on a single microarray platform. The sample sets were augmented with carefully selected and manually curated data from public repositories coming from multiple experiments and generated on different platforms.

To design and implement the DNN architectures, BioTime partnered with the Pharmaceutical Artificial Intelligence (Pharma.AI) division of Insilico Medicine, Inc., a Baltimore-based bioinformatics company specializing in biomarker and drug development for aging and age-related diseases. There are many potential applications of this system in multiple areas ranging from cancer research and quality control to in vivo regeneration. Embryonic.AI may have future applications in comparing multiple biopsies of patients' tumor to search for cancer stem cells. One of the major challenges in organ engineering for drug testing is quality control of the engineered human tissues to ensure that it closely resembles the expected results. Embryonic.AI may have future applications in analyzing the embryonic state of these tissues and evaluating the effectiveness of many drugs in a high-throughput manner.

Recently Insilico Medicine published several key papers on applying deep learning techniques to biomedical applications in influential peer-reviewed journals including "Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data" in "Molecular Pharmaceutics" and ACS publication. The paper received the Editors' Choice Award from the American Chemical Society. "Applications of Deep Learning in Biomedicine" in also in Molecular Pharmaceutics and "Deep biomarkers of human aging: Application of deep neural networks to biomarker development" in Aging, one of the highest-impact journals in aging research. These studies were presented at the Machine Intelligence Summit Berlin on June 30th.
-end-
About Insilico Medicine

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia, and Poland hiring talent through hackathons and competitions. The company aims to transform drug discovery and development by rapidly generating and validating thousands of new leads for multiple diseases and developing novel biomarkers using a technique called deep learning. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division, the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Since 2014 company scientists published over 40 research papers in peer-reviewed journals and collaborated with over 150 academics, biotechnology and pharmaceutical companies worldwide. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

InSilico Medicine, Inc.

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Don't Fear Math
Why do many of us hate, even fear math? Why are we convinced we're bad at it? This hour, TED speakers explore the myths we tell ourselves and how changing our approach can unlock the beauty of math. Guests include budgeting specialist Phylecia Jones, mathematician and educator Dan Finkel, math teacher Eddie Woo, educator Masha Gershman, and radio personality and eternal math nerd Adam Spencer.
Now Playing: Science for the People

#518 With Genetic Knowledge Comes the Need for Counselling
This week we delve into genetic testing - for yourself and your future children. We speak with Jane Tiller, lawyer and genetic counsellor, about genetic tests that are available to the public, and what to do with the results of these tests. And we talk with Noam Shomron, associate professor at the Sackler School of Medicine at Tel Aviv University, about technological advancements his lab has made in the genetic testing of fetuses.